# SETDB2 Mitigates Podocyte Dysfunction in Diabetic Kidney Disease Through Epigenetic Silencing of SMAD3

**Authors:** Lanfang Li, Shimin Jiang, Qi Jin, Peng Qu, Yingjie Guo, Xushan Lan, Xinyu Li, Cuiting Sun, Sinan Ai, Xin Li, Weiliang Sun, Jing Guo, Wenge Li, Liang Peng, Lihong Liu

PMC · DOI: 10.1002/advs.202516984 · Advanced Science · 2025-11-29

## TL;DR

This study shows that SETDB2 helps protect kidney cells in diabetic kidney disease by silencing a harmful gene through epigenetic changes.

## Contribution

The study identifies SETDB2 as a novel epigenetic regulator of podocyte dysfunction in DKD and reveals its mechanism involving SMAD3 and TCF21.

## Key findings

- SETDB2 deficiency worsens DKD, while its overexpression protects kidney function.
- SETDB2 represses SMAD3 by increasing H3K9me3 at its promoter.
- TCF21 activates Setdb2 transcription by binding to its promoter.

## Abstract

Podocyte dysfunction represents both an early pathological hallmark and a key driver of proteinuria in diabetic kidney disease (DKD); nevertheless, the potential epigenetic regulatory mechanisms remain poorly defined. Here, the histone methyltransferase SETDB2 is identified as a pivotal epigenetic suppressor of podocyte dysfunction and DKD progression. Glomerular SETDB2 expression exhibits a significant reduce in both DKD patients and mouse models, showing an inverse correlation with disease severity. Podocyte‐specific SETDB2 deficiency exacerbates podocytes dysfunction and accelerates DKD progression, whereas its overexpression exerts renal protective effects. Mechanistically, SETDB2 directly enhances H3K9 trimethylation at the Smad3 promoter, thereby repressing SMAD3 expression and activation, ultimately preserving podocyte function. Notably, it identifies TCF21, a transcription factor downregulated in DKD, as a direct upstream regulator of Setdb2 expression via binding to promoter and activating its transcription. Collectively, these findings establish SETDB2 as a critical regulator of podocyte integrity and a promising therapeutic target for DKD.

SETDB2 epigenetically represses Smad3 transcription by increasing H3K9me3 enrichment at its promoter, thereby mitigating podocyte dysfunction in DKD. The transcription factor TCF21 binds directly to the Setdb2 promoter and enhances its expression in podocytes.

## Linked entities

- **Genes:** SETDB2 (SET domain bifurcated histone lysine methyltransferase 2) [NCBI Gene 83852], SMAD3 (SMAD family member 3) [NCBI Gene 4088], SETDB2 (SET domain bifurcated histone lysine methyltransferase 2) [NCBI Gene 83852], TCF21 (transcription factor 21) [NCBI Gene 6943]
- **Proteins:** SETDB2 (SET domain bifurcated histone lysine methyltransferase 2), SMAD3 (SMAD family member 3), TCF21 (transcription factor 21)
- **Diseases:** diabetic kidney disease (MONDO:0005016), DKD (MONDO:0005016)

## Full-text entities

- **Genes:** TCF21 (transcription factor 21) [NCBI Gene 6943] {aka POD1, bHLHa23}, SETDB2 (SET domain bifurcated histone lysine methyltransferase 2) [NCBI Gene 83852] {aka C13orf4, CLLD8, CLLL8, KMT1F}, SMAD3 (SMAD family member 3) [NCBI Gene 4088] {aka HSPC193, HsT17436, JV15-2, LDS1C, LDS3, MADH3}
- **Diseases:** DKD (MESH:D003928), proteinuria (MESH:D011507)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12904062/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12904062/full.md

## References

49 references — full list in the complete paper: https://tomesphere.com/paper/PMC12904062/full.md

---
Source: https://tomesphere.com/paper/PMC12904062